This investigation underscores the potential advantage of leveraging the combined impact of Lp‐PLA2 in conjunction with Lp(a) as a more precise and cost‐effective predictive tool for the risk of recurrence stroke in patients with AIS. The gene discussed is LPA; the disease is Stroke.